Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • FDA
  • Financing
  • General
  • Health Care
  • News
  • Offerings
  • Penny Stocks

Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today?

By Vandana Singh
December 21, 12:07 PM
On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form of C1s responsible for propagating classical pathway 

ANNX

Read More
1 minute read
  • Biotech
  • Financing
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Offerings
  • Penny Stocks
  • Trading Ideas

Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today?

By Vandana Singh
December 21, 12:02 PM
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million, 

GILD

Read More
2 minute read
  • Equities
  • FDA
  • General
  • Markets
  • News

Philips Recalls Medical Imaging Device Due To A Risk Of Explosion; FDA Identifies Recall As Most Serious Type

By Shivani Kumaresan
December 21, 10:48 AM
Koninklijke Philips N.V. (NYSE: PHG) has recalled some Panorama 1.0T HFO machines. The magnetic resonance (MR) system is used to take different kinds of images that show what's inside the body and can help health care providers make a diagnosis.

PHG

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News

Autoimmune Disease Player Immunovant’s Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%

By Vandana Singh
December 21, 9:57 AM
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in 

IMVT

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug

By Vandana Singh
December 21, 9:54 AM
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at 

CALT

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News

Merck’s Chronic Cough Treatment Candidate Receives Second Time FDA Rejection

By Vandana Singh
December 21, 9:51 AM
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or unexplained chronic 

GSK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

c

By Vandana Singh
December 21, 9:48 AM
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr

SNY

Read More
1 minute read
  • Biotech
  • General
  • News

NightHawk Biosciences Announces Completion Of Demonstration Run For A Top-Tier NIH And DTRA Funded Research University

By Benzinga Newsdesk
December 21, 9:47 AM
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio

NHWK

Read More
2 minute read
  • Biotech
  • General
  • News

RenovoRx Engages Oklahoma University Health As First Clinical Site In Preparation For The Pivotal Phase III CouGar Clinical Trial In Bile Duct Cancer

By Benzinga Newsdesk
December 21, 9:33 AM
This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor CancerRenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a

RNXT

Read More
3 minute read
  • Biotech
  • General
  • News

IO Biotech Announces First Patient Dosed In Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

By Benzinga Newsdesk
December 21, 9:32 AM
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been

IOBT

Posts pagination

Previous 1 … 149 150 151 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service